Request Demo
Recent blog posts
Latest Hotspot
8 min read
Purinostat Mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Purinostat Mesylate: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
AmbiVax-C Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
AmbiVax-C: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Simmitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Simmitinib: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Anbenitamab repodatecan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Anbenitamab repodatecan: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Navtemadlin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Navtemadlin: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Obefazimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Obefazimod: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Bisantrene dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Bisantrene dihydrochloride: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Strontium Ranelate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Strontium Ranelate: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Seltorexant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Seltorexant: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Pozdeutinurad Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Pozdeutinurad: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Eneboparatide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Eneboparatide: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Ibutamoren Mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Ibutamoren Mesylate: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.